Actively Recruiting
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Led by M.D. Anderson Cancer Center · Updated on 2026-04-13
20
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
CONDITIONS
Official Title
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and above
- English speaking with the ability to give informed consent
- Diagnosis by a rheumatologist of inflammatory arthritis or polymyalgia rheumatica immune-related adverse events after immune checkpoint inhibitor therapy
You will not qualify if you...
- Acutely life-threatening or worsening cancer
- Hearing impairment that limits participation in verbal interviews
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
Y
Y. Jeff Li, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here